MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
491.49
+4.17
+0.86%
After Hours: 500.00 +8.51 +1.73% 19:59 02/18 EST
OPEN
486.71
PREV CLOSE
487.32
HIGH
498.10
LOW
480.00
VOLUME
316.82K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
265.00
MARKET CAP
11.16B
P/E (TTM)
-37.7866
1D
5D
1M
3M
1Y
5Y
1D
Here are the major earnings before the open Thursday
Seeking Alpha · 4h ago
Paulson Trims Madrigal Stake As Equity Grants Highlight Valuation Gap
Simply Wall St · 6h ago
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Preview
Seeking Alpha · 10h ago
Earnings Preview For Madrigal Pharmaceuticals
Benzinga · 12h ago
Paulson & Co. takes new position in Solstice Advanced Materials, exits Trilogy Metals in Q4 moves
Seeking Alpha · 1d ago
Paulson buys Solstice, exits Honeywell in Q4
TipRanks · 1d ago
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Reuters · 1d ago
MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.